Jacobs Levy Equity Management
CORT icon

Jacobs Levy Equity Management’s Corcept Therapeutics CORT Stock Holding History

Jacobs Levy Equity Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-3,828
Closed -$318K – 947
2025
Q3 		$318K Sell
3,828
-451,623
-99% -$32.7M ﹤0.01% 874
2025
Q2 		$33.4M Sell
455,451
-894,231
-66% -$64.8M 0.13% 160
2025
Q1 		$154M Sell
1,349,682
-27,199
-2% -$1.66M 0.61% 31
2024
Q4 		$69.4M Buy
1,376,881
+153,100
+13% +$8.02M 0.25% 100
2024
Q3 		$56.6M Buy
1,223,781
+352,947
+41% +$12.5M 0.22% 116
2024
Q2 		$28.3M Buy
870,834
+139,366
+19% +$3.82M 0.12% 180
2024
Q1 		$18.4M Buy
+731,468
New +$17.3M 0.08% 217
2020
Q4 		– Sell
-704,024
Closed -$12.3M – 1027
2020
Q3 		$12.3M Sell
704,024
-165,376
-19% -$2.64M 0.13% 179
2020
Q2 		$14.6M Buy
869,400
+371,270
+75% +$5.22M 0.16% 156
2020
Q1 		$5.92M Buy
+498,130
New +$6.16M 0.08% 264
2018
Q1 		– Sell
-49,310
Closed -$891K – 1008
2017
Q4 		$891K Buy
49,310
+29,500
+149% +$534K 0.02% 637
2017
Q3 		$382K Buy
+19,810
New +$295K 0.01% 746
2015
Q4 		– Sell
-16,200
Closed -$61K – 822
2015
Q3 		$61K Buy
+16,200
New +$82.2K ﹤0.01% 783

Other funds holding CORT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $2.83B AUM 21.61% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jacobs Levy Equity Management's CORT Position: Q4 2025 in Review

Jacobs Levy Equity Management sold out of Corcept Therapeutics (CORT) in Q4 2025, closing a stake of 3,828 shares — an estimated $318K sold.

Jacobs Levy Equity Management first reported a position in CORT in Q3 2015 and held it in 13 quarters. The position peaked at $154M in Q1 2025. 389 funds tracked by Wall St. Rank hold CORT as of Q4 2025.

  • Jacobs Levy Equity Management reported no remaining Corcept Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jacobs Levy Equity Management sold 3,828 Corcept Therapeutics shares in Q4 2025, an estimated $318K.
  • Jacobs Levy Equity Management first reported a position in Corcept Therapeutics in Q3 2015 and held it in 13 quarters.
  • Jacobs Levy Equity Management's Corcept Therapeutics position peaked at $154M in Q1 2025.
  • 389 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2025.

Based on Jacobs Levy Equity Management's 13F filing for Q4 2025, filed 13 Feb 2026.